

---

## Product Data Sheet

---

Product Name: Triamcinolone

Cat. No.: GC10434

### Chemical Properties

Cas. No. 124-94-7

Chemical Name (8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

SMILES CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)OFormula C<sub>21</sub>H<sub>27</sub>FO<sub>6</sub>

M.Wt

394.43

Solubility ≥ 11.95mg/mL in DMSO

Storage

Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure 

### Background

Triamcinolone is a long-acting synthetic corticosteroid. Target: Glucocorticoid Receptor. Dimethyl fumarate is an anti-inflammatory. It is indicated for multiple sclerosis patients with relapsing forms and is also being investigated for the treatment of psoriasis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress [1]. The mean duration of follow-up was 40 months. The rate of decline in the FEV1 after bronchodilator use was similar in the 559 participants in the triamcinolone group and the 557 participants in the placebo group (44.2±2.9 vs. 47.0±3.0 ml per year, P= 0.50). Members of the triamcinolone group had fewer respiratory symptoms during the course of the study (21.1 per 100 person-years vs. 28.2 per 100 person-years, P=0.005) and had fewer visits to a physician because of a respiratory illness (1.2

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

per 100 person-years vs. 2.1 per 100 person-years,  $P=0.03$ ). Those taking triamcinolone also had lower airway reactivity in response to methacholine challenge at 9 months and 33 months ( $P=0.02$  for both comparisons) [2].

### References:

[1]. <http://www.drugbank.ca/drugs/DB08908#targets>

[2]. Lung Health Study Research, G., Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. *N Engl J Med*, 2000. 343(26): p. 1902-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: [tech@glpbio.com](mailto:tech@glpbio.com)**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**